

September 20, 2022

BSE Limited Code: 532321

1st Floor, P J Towers, Dalal Street, Mumbai-400001

National Stock Exchange of India Limited Code: Zyduslife

Exchange Plaza, 5th Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East), Mumbai-400051

Re.: Press Release

Dear Sir / Madam,

Please find enclosed a copy of press release dated September 20, 2022 titled "**Zydus launches Lenalidomide Capsules**".

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully, For, **ZYDUS LIFESCIENCES LIMITED**

DHAVAL N. SONI COMPANY SECRETARY

Encl.: As above

website: www.zyduslife.com | CIN: L24230GJ1995PLC025878





Zydus launches Lenalidomide Capsules

Ahmedabad, India, 20 September, 2022

Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited) has launched Lenalidomide Capsules in the US. The company had earlier received final approvals for 5 mg, 10 mg, 15 mg and 25 mg strengths and tentative approvals for 2.5 mg and 20 mg strength. USRLD: Revlimid[®].

Lenalidomide is used to treat various types of cancers. It works by slowing or stopping the growth of cancer cells. It is also used to treat anemia in patients with certain blood/bone marrow disorders (myelodysplastic syndromes-MDS). The drug is being manufactured at the group's formulation manufacturing facility at Ahmedabad SEZ, India.

Lenalidomide had annual sales of USD 2.86 bn in the United States, according to IQVIA MAT July 2022.



For further information please contact: The Corporate Communications Department

Zydus Lifesciences Limited

(formerly known as Cadila Healthcare Limited)

Regd. Office : 'Zydus Corporate Park',

Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382 481, Gujarat, India. | Phone: +91-79-71800000, +91-79-48040000 | website: www.zyduslife.com CIN: L24230GJ1995PLC025878